Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Geisinger Medical Group
mi
from
State College, PA
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Geisinger Medical Group
mi
from
State College, PA
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Geisinger Wyoming Valley Medical Center
mi
from
Wilkes-Barre, PA
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Geisinger Wyoming Valley Medical Center
mi
from
Wilkes-Barre, PA
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Fredericksburg Oncology Inc
mi
from
Fredericksburg, VA
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Fredericksburg Oncology Inc
mi
from
Fredericksburg, VA
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Midelfort Clinic-Clairemont Campus
mi
from
Eau Claire, WI
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Midelfort Clinic-Clairemont Campus
mi
from
Eau Claire, WI
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Mayo Clinic Health System Eau Claire Hospital - Luther Campus
mi
from
Eau Claire, WI
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Mayo Clinic Health System Eau Claire Hospital - Luther Campus
mi
from
Eau Claire, WI
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Green Bay Oncology at Saint Vincent Hospital
mi
from
Green Bay, WI
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Green Bay Oncology at Saint Vincent Hospital
mi
from
Green Bay, WI
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Saint Vincent Hospital
mi
from
Green Bay, WI
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Saint Vincent Hospital
mi
from
Green Bay, WI
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Green Bay Oncology Limited at Saint Mary's Hospital
mi
from
Green Bay, WI
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Green Bay Oncology Limited at Saint Mary's Hospital
mi
from
Green Bay, WI
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Saint Mary's Hospital
mi
from
Green Bay, WI
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Saint Mary's Hospital
mi
from
Green Bay, WI
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Holy Family Memorial Hospital
mi
from
Manitowoc, WI
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Holy Family Memorial Hospital
mi
from
Manitowoc, WI
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Bay Area Medical Center
mi
from
Marinette, WI
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Bay Area Medical Center
mi
from
Marinette, WI
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Green Bay Oncology - Oconto Falls
mi
from
Oconto Falls, WI
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Green Bay Oncology - Oconto Falls
mi
from
Oconto Falls, WI
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Green Bay Oncology - Sturgeon Bay
mi
from
Sturgeon Bay, WI
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Green Bay Oncology - Sturgeon Bay
mi
from
Sturgeon Bay, WI
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Welch Cancer Center
mi
from
Sheridan, WY
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Welch Cancer Center
mi
from
Sheridan, WY
Click here to add this to my saved trials
Collect Long-term Data on Subjects Following Participation in Previous EMD 531444 (L-BLP25 or BLP25 Liposome Vaccine) Clinical Trials
An Open-label Trial to Collect Long-term Data on Subjects Following Participation in Previous EMD 531444 (L-BLP25 or BLP25 Liposome Vaccine) Clinical Trials
Status: Enrolling
Updated:  7/31/2015
U.S. Medical Information
mi
from
Rockland, MA
Collect Long-term Data on Subjects Following Participation in Previous EMD 531444 (L-BLP25 or BLP25 Liposome Vaccine) Clinical Trials
An Open-label Trial to Collect Long-term Data on Subjects Following Participation in Previous EMD 531444 (L-BLP25 or BLP25 Liposome Vaccine) Clinical Trials
Status: Enrolling
Updated: 7/31/2015
U.S. Medical Information
mi
from
Rockland, MA
Click here to add this to my saved trials
Collect Long-term Data on Subjects Following Participation in Previous EMD 531444 (L-BLP25 or BLP25 Liposome Vaccine) Clinical Trials
An Open-label Trial to Collect Long-term Data on Subjects Following Participation in Previous EMD 531444 (L-BLP25 or BLP25 Liposome Vaccine) Clinical Trials
Status: Enrolling
Updated:  7/31/2015
Merck KGaA Communication Center
mi
from
Darmstadt,
Collect Long-term Data on Subjects Following Participation in Previous EMD 531444 (L-BLP25 or BLP25 Liposome Vaccine) Clinical Trials
An Open-label Trial to Collect Long-term Data on Subjects Following Participation in Previous EMD 531444 (L-BLP25 or BLP25 Liposome Vaccine) Clinical Trials
Status: Enrolling
Updated: 7/31/2015
Merck KGaA Communication Center
mi
from
Darmstadt,
Click here to add this to my saved trials
Phase I/II Study of Irinotecan and Temsirolimus in Patients With Refractory Sarcomas
Phase I/II Study of Irinotecan and Temsirolimus in Patients With Refractory Sarcomas
Status: Enrolling
Updated:  8/2/2015
University of New Mexico Cancer Center
mi
from
Albuquerque, NM
Phase I/II Study of Irinotecan and Temsirolimus in Patients With Refractory Sarcomas
Phase I/II Study of Irinotecan and Temsirolimus in Patients With Refractory Sarcomas
Status: Enrolling
Updated: 8/2/2015
University of New Mexico Cancer Center
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Combination of Oxaliplatin, Capecitabine, and Celecoxib With Concurrent Radiation for Rectal Cancer
A Phase II Trial Using a Combination of Oxaliplatin, Capecitabine, and Celecoxib With Concurrent Radiation for Patients With Newly Diagnosed Resectable Rectal Cancer
Status: Enrolling
Updated:  8/3/2015
University of New Mexico Cancer Center
mi
from
Albuquerque, NM
Combination of Oxaliplatin, Capecitabine, and Celecoxib With Concurrent Radiation for Rectal Cancer
A Phase II Trial Using a Combination of Oxaliplatin, Capecitabine, and Celecoxib With Concurrent Radiation for Patients With Newly Diagnosed Resectable Rectal Cancer
Status: Enrolling
Updated: 8/3/2015
University of New Mexico Cancer Center
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Combination of Oxaliplatin, Capecitabine, and Celecoxib With Concurrent Radiation for Rectal Cancer
A Phase II Trial Using a Combination of Oxaliplatin, Capecitabine, and Celecoxib With Concurrent Radiation for Patients With Newly Diagnosed Resectable Rectal Cancer
Status: Enrolling
Updated:  8/3/2015
Hematology Oncology Associates, PC
mi
from
Albuquerque, NM
Combination of Oxaliplatin, Capecitabine, and Celecoxib With Concurrent Radiation for Rectal Cancer
A Phase II Trial Using a Combination of Oxaliplatin, Capecitabine, and Celecoxib With Concurrent Radiation for Patients With Newly Diagnosed Resectable Rectal Cancer
Status: Enrolling
Updated: 8/3/2015
Hematology Oncology Associates, PC
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Combination of Oxaliplatin, Capecitabine, and Celecoxib With Concurrent Radiation for Rectal Cancer
A Phase II Trial Using a Combination of Oxaliplatin, Capecitabine, and Celecoxib With Concurrent Radiation for Patients With Newly Diagnosed Resectable Rectal Cancer
Status: Enrolling
Updated:  8/3/2015
New Mexico Cancer Care Associates
mi
from
Santa Fe, NM
Combination of Oxaliplatin, Capecitabine, and Celecoxib With Concurrent Radiation for Rectal Cancer
A Phase II Trial Using a Combination of Oxaliplatin, Capecitabine, and Celecoxib With Concurrent Radiation for Patients With Newly Diagnosed Resectable Rectal Cancer
Status: Enrolling
Updated: 8/3/2015
New Mexico Cancer Care Associates
mi
from
Santa Fe, NM
Click here to add this to my saved trials
177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms
177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms
Status: Enrolling
Updated:  8/3/2015
Excel Diagnostics and Nuclear Oncology Center
mi
from
Houston, TX
177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms
177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms
Status: Enrolling
Updated: 8/3/2015
Excel Diagnostics and Nuclear Oncology Center
mi
from
Houston, TX
Click here to add this to my saved trials
Head to Head Study Epi proColon and FIT
Comparison of the Performance of the Epi proColon and Fecal ImmunochemicalTest Post Colonoscopy in Subjects With Colorectal Cancer and Pre Colonoscopy in Subjects From a Guideline-Eligible Screening Population
Status: Enrolling
Updated:  8/3/2015
Achieve Clinical Research
mi
from
Birmingham, AL
Head to Head Study Epi proColon and FIT
Comparison of the Performance of the Epi proColon and Fecal ImmunochemicalTest Post Colonoscopy in Subjects With Colorectal Cancer and Pre Colonoscopy in Subjects From a Guideline-Eligible Screening Population
Status: Enrolling
Updated: 8/3/2015
Achieve Clinical Research
mi
from
Birmingham, AL
Click here to add this to my saved trials
Head to Head Study Epi proColon and FIT
Comparison of the Performance of the Epi proColon and Fecal ImmunochemicalTest Post Colonoscopy in Subjects With Colorectal Cancer and Pre Colonoscopy in Subjects From a Guideline-Eligible Screening Population
Status: Enrolling
Updated:  8/3/2015
Visions Clinical Research
mi
from
Tucson, AZ
Head to Head Study Epi proColon and FIT
Comparison of the Performance of the Epi proColon and Fecal ImmunochemicalTest Post Colonoscopy in Subjects With Colorectal Cancer and Pre Colonoscopy in Subjects From a Guideline-Eligible Screening Population
Status: Enrolling
Updated: 8/3/2015
Visions Clinical Research
mi
from
Tucson, AZ
Click here to add this to my saved trials
Head to Head Study Epi proColon and FIT
Comparison of the Performance of the Epi proColon and Fecal ImmunochemicalTest Post Colonoscopy in Subjects With Colorectal Cancer and Pre Colonoscopy in Subjects From a Guideline-Eligible Screening Population
Status: Enrolling
Updated:  8/3/2015
South Orange County Surgical Medical Group
mi
from
Laguna Hills, CA
Head to Head Study Epi proColon and FIT
Comparison of the Performance of the Epi proColon and Fecal ImmunochemicalTest Post Colonoscopy in Subjects With Colorectal Cancer and Pre Colonoscopy in Subjects From a Guideline-Eligible Screening Population
Status: Enrolling
Updated: 8/3/2015
South Orange County Surgical Medical Group
mi
from
Laguna Hills, CA
Click here to add this to my saved trials
Head to Head Study Epi proColon and FIT
Comparison of the Performance of the Epi proColon and Fecal ImmunochemicalTest Post Colonoscopy in Subjects With Colorectal Cancer and Pre Colonoscopy in Subjects From a Guideline-Eligible Screening Population
Status: Enrolling
Updated:  8/3/2015
Gastroenterology Associates of Fairfield County
mi
from
Bridgeport, CT
Head to Head Study Epi proColon and FIT
Comparison of the Performance of the Epi proColon and Fecal ImmunochemicalTest Post Colonoscopy in Subjects With Colorectal Cancer and Pre Colonoscopy in Subjects From a Guideline-Eligible Screening Population
Status: Enrolling
Updated: 8/3/2015
Gastroenterology Associates of Fairfield County
mi
from
Bridgeport, CT
Click here to add this to my saved trials
Head to Head Study Epi proColon and FIT
Comparison of the Performance of the Epi proColon and Fecal ImmunochemicalTest Post Colonoscopy in Subjects With Colorectal Cancer and Pre Colonoscopy in Subjects From a Guideline-Eligible Screening Population
Status: Enrolling
Updated:  8/3/2015
Middlesex Hospital Cancer Center
mi
from
Middletown, CT
Head to Head Study Epi proColon and FIT
Comparison of the Performance of the Epi proColon and Fecal ImmunochemicalTest Post Colonoscopy in Subjects With Colorectal Cancer and Pre Colonoscopy in Subjects From a Guideline-Eligible Screening Population
Status: Enrolling
Updated: 8/3/2015
Middlesex Hospital Cancer Center
mi
from
Middletown, CT
Click here to add this to my saved trials
Head to Head Study Epi proColon and FIT
Comparison of the Performance of the Epi proColon and Fecal ImmunochemicalTest Post Colonoscopy in Subjects With Colorectal Cancer and Pre Colonoscopy in Subjects From a Guideline-Eligible Screening Population
Status: Enrolling
Updated:  8/3/2015
Center for Gastrointestinal Disorders
mi
from
Hollywood, FL
Head to Head Study Epi proColon and FIT
Comparison of the Performance of the Epi proColon and Fecal ImmunochemicalTest Post Colonoscopy in Subjects With Colorectal Cancer and Pre Colonoscopy in Subjects From a Guideline-Eligible Screening Population
Status: Enrolling
Updated: 8/3/2015
Center for Gastrointestinal Disorders
mi
from
Hollywood, FL
Click here to add this to my saved trials
Head to Head Study Epi proColon and FIT
Comparison of the Performance of the Epi proColon and Fecal ImmunochemicalTest Post Colonoscopy in Subjects With Colorectal Cancer and Pre Colonoscopy in Subjects From a Guideline-Eligible Screening Population
Status: Enrolling
Updated:  8/3/2015
Advance Medical Research Service Corp
mi
from
Miami, FL
Head to Head Study Epi proColon and FIT
Comparison of the Performance of the Epi proColon and Fecal ImmunochemicalTest Post Colonoscopy in Subjects With Colorectal Cancer and Pre Colonoscopy in Subjects From a Guideline-Eligible Screening Population
Status: Enrolling
Updated: 8/3/2015
Advance Medical Research Service Corp
mi
from
Miami, FL
Click here to add this to my saved trials
Head to Head Study Epi proColon and FIT
Comparison of the Performance of the Epi proColon and Fecal ImmunochemicalTest Post Colonoscopy in Subjects With Colorectal Cancer and Pre Colonoscopy in Subjects From a Guideline-Eligible Screening Population
Status: Enrolling
Updated:  8/3/2015
Accord Clinical Research
mi
from
Port Orange, FL
Head to Head Study Epi proColon and FIT
Comparison of the Performance of the Epi proColon and Fecal ImmunochemicalTest Post Colonoscopy in Subjects With Colorectal Cancer and Pre Colonoscopy in Subjects From a Guideline-Eligible Screening Population
Status: Enrolling
Updated: 8/3/2015
Accord Clinical Research
mi
from
Port Orange, FL
Click here to add this to my saved trials
Head to Head Study Epi proColon and FIT
Comparison of the Performance of the Epi proColon and Fecal ImmunochemicalTest Post Colonoscopy in Subjects With Colorectal Cancer and Pre Colonoscopy in Subjects From a Guideline-Eligible Screening Population
Status: Enrolling
Updated:  8/3/2015
Stedman Clinical Trials
mi
from
Tampa, FL
Head to Head Study Epi proColon and FIT
Comparison of the Performance of the Epi proColon and Fecal ImmunochemicalTest Post Colonoscopy in Subjects With Colorectal Cancer and Pre Colonoscopy in Subjects From a Guideline-Eligible Screening Population
Status: Enrolling
Updated: 8/3/2015
Stedman Clinical Trials
mi
from
Tampa, FL
Click here to add this to my saved trials
Head to Head Study Epi proColon and FIT
Comparison of the Performance of the Epi proColon and Fecal ImmunochemicalTest Post Colonoscopy in Subjects With Colorectal Cancer and Pre Colonoscopy in Subjects From a Guideline-Eligible Screening Population
Status: Enrolling
Updated:  8/3/2015
Springfield Clinic
mi
from
Springfield, IL
Head to Head Study Epi proColon and FIT
Comparison of the Performance of the Epi proColon and Fecal ImmunochemicalTest Post Colonoscopy in Subjects With Colorectal Cancer and Pre Colonoscopy in Subjects From a Guideline-Eligible Screening Population
Status: Enrolling
Updated: 8/3/2015
Springfield Clinic
mi
from
Springfield, IL
Click here to add this to my saved trials
Head to Head Study Epi proColon and FIT
Comparison of the Performance of the Epi proColon and Fecal ImmunochemicalTest Post Colonoscopy in Subjects With Colorectal Cancer and Pre Colonoscopy in Subjects From a Guideline-Eligible Screening Population
Status: Enrolling
Updated:  8/3/2015
New Orleans Research Institute
mi
from
Metairie, LA
Head to Head Study Epi proColon and FIT
Comparison of the Performance of the Epi proColon and Fecal ImmunochemicalTest Post Colonoscopy in Subjects With Colorectal Cancer and Pre Colonoscopy in Subjects From a Guideline-Eligible Screening Population
Status: Enrolling
Updated: 8/3/2015
New Orleans Research Institute
mi
from
Metairie, LA
Click here to add this to my saved trials
Head to Head Study Epi proColon and FIT
Comparison of the Performance of the Epi proColon and Fecal ImmunochemicalTest Post Colonoscopy in Subjects With Colorectal Cancer and Pre Colonoscopy in Subjects From a Guideline-Eligible Screening Population
Status: Enrolling
Updated:  8/3/2015
Louisiana Research Center, LLC
mi
from
Shreveport, LA
Head to Head Study Epi proColon and FIT
Comparison of the Performance of the Epi proColon and Fecal ImmunochemicalTest Post Colonoscopy in Subjects With Colorectal Cancer and Pre Colonoscopy in Subjects From a Guideline-Eligible Screening Population
Status: Enrolling
Updated: 8/3/2015
Louisiana Research Center, LLC
mi
from
Shreveport, LA
Click here to add this to my saved trials
Head to Head Study Epi proColon and FIT
Comparison of the Performance of the Epi proColon and Fecal ImmunochemicalTest Post Colonoscopy in Subjects With Colorectal Cancer and Pre Colonoscopy in Subjects From a Guideline-Eligible Screening Population
Status: Enrolling
Updated:  8/3/2015
Metropolitan Gastroenterology Group, P.C.
mi
from
Chevy Chase, MD
Head to Head Study Epi proColon and FIT
Comparison of the Performance of the Epi proColon and Fecal ImmunochemicalTest Post Colonoscopy in Subjects With Colorectal Cancer and Pre Colonoscopy in Subjects From a Guideline-Eligible Screening Population
Status: Enrolling
Updated: 8/3/2015
Metropolitan Gastroenterology Group, P.C.
mi
from
Chevy Chase, MD
Click here to add this to my saved trials
Head to Head Study Epi proColon and FIT
Comparison of the Performance of the Epi proColon and Fecal ImmunochemicalTest Post Colonoscopy in Subjects With Colorectal Cancer and Pre Colonoscopy in Subjects From a Guideline-Eligible Screening Population
Status: Enrolling
Updated:  8/3/2015
Commonwealth Clinical Trials
mi
from
Brockton, MA
Head to Head Study Epi proColon and FIT
Comparison of the Performance of the Epi proColon and Fecal ImmunochemicalTest Post Colonoscopy in Subjects With Colorectal Cancer and Pre Colonoscopy in Subjects From a Guideline-Eligible Screening Population
Status: Enrolling
Updated: 8/3/2015
Commonwealth Clinical Trials
mi
from
Brockton, MA
Click here to add this to my saved trials
Head to Head Study Epi proColon and FIT
Comparison of the Performance of the Epi proColon and Fecal ImmunochemicalTest Post Colonoscopy in Subjects With Colorectal Cancer and Pre Colonoscopy in Subjects From a Guideline-Eligible Screening Population
Status: Enrolling
Updated:  8/3/2015
Beaumont Hospital
mi
from
Royal Oak, MI
Head to Head Study Epi proColon and FIT
Comparison of the Performance of the Epi proColon and Fecal ImmunochemicalTest Post Colonoscopy in Subjects With Colorectal Cancer and Pre Colonoscopy in Subjects From a Guideline-Eligible Screening Population
Status: Enrolling
Updated: 8/3/2015
Beaumont Hospital
mi
from
Royal Oak, MI
Click here to add this to my saved trials
Head to Head Study Epi proColon and FIT
Comparison of the Performance of the Epi proColon and Fecal ImmunochemicalTest Post Colonoscopy in Subjects With Colorectal Cancer and Pre Colonoscopy in Subjects From a Guideline-Eligible Screening Population
Status: Enrolling
Updated:  8/3/2015
Troy Gastroenterology PC Center for Digestive Health
mi
from
Troy, MI
Head to Head Study Epi proColon and FIT
Comparison of the Performance of the Epi proColon and Fecal ImmunochemicalTest Post Colonoscopy in Subjects With Colorectal Cancer and Pre Colonoscopy in Subjects From a Guideline-Eligible Screening Population
Status: Enrolling
Updated: 8/3/2015
Troy Gastroenterology PC Center for Digestive Health
mi
from
Troy, MI
Click here to add this to my saved trials
Head to Head Study Epi proColon and FIT
Comparison of the Performance of the Epi proColon and Fecal ImmunochemicalTest Post Colonoscopy in Subjects With Colorectal Cancer and Pre Colonoscopy in Subjects From a Guideline-Eligible Screening Population
Status: Enrolling
Updated:  8/3/2015
Research Medical Center
mi
from
Kansas City, MO
Head to Head Study Epi proColon and FIT
Comparison of the Performance of the Epi proColon and Fecal ImmunochemicalTest Post Colonoscopy in Subjects With Colorectal Cancer and Pre Colonoscopy in Subjects From a Guideline-Eligible Screening Population
Status: Enrolling
Updated: 8/3/2015
Research Medical Center
mi
from
Kansas City, MO
Click here to add this to my saved trials
Head to Head Study Epi proColon and FIT
Comparison of the Performance of the Epi proColon and Fecal ImmunochemicalTest Post Colonoscopy in Subjects With Colorectal Cancer and Pre Colonoscopy in Subjects From a Guideline-Eligible Screening Population
Status: Enrolling
Updated:  8/3/2015
Binghampton Gastroenterology Associates
mi
from
Binghampton, NY
Head to Head Study Epi proColon and FIT
Comparison of the Performance of the Epi proColon and Fecal ImmunochemicalTest Post Colonoscopy in Subjects With Colorectal Cancer and Pre Colonoscopy in Subjects From a Guideline-Eligible Screening Population
Status: Enrolling
Updated: 8/3/2015
Binghampton Gastroenterology Associates
mi
from
Binghampton, NY
Click here to add this to my saved trials
Head to Head Study Epi proColon and FIT
Comparison of the Performance of the Epi proColon and Fecal ImmunochemicalTest Post Colonoscopy in Subjects With Colorectal Cancer and Pre Colonoscopy in Subjects From a Guideline-Eligible Screening Population
Status: Enrolling
Updated:  8/3/2015
Bassett Healthcare Center
mi
from
Cooperstown, NY
Head to Head Study Epi proColon and FIT
Comparison of the Performance of the Epi proColon and Fecal ImmunochemicalTest Post Colonoscopy in Subjects With Colorectal Cancer and Pre Colonoscopy in Subjects From a Guideline-Eligible Screening Population
Status: Enrolling
Updated: 8/3/2015
Bassett Healthcare Center
mi
from
Cooperstown, NY
Click here to add this to my saved trials
Head to Head Study Epi proColon and FIT
Comparison of the Performance of the Epi proColon and Fecal ImmunochemicalTest Post Colonoscopy in Subjects With Colorectal Cancer and Pre Colonoscopy in Subjects From a Guideline-Eligible Screening Population
Status: Enrolling
Updated:  8/3/2015
Mid Hudson Medical Research
mi
from
New Windsor, NY
Head to Head Study Epi proColon and FIT
Comparison of the Performance of the Epi proColon and Fecal ImmunochemicalTest Post Colonoscopy in Subjects With Colorectal Cancer and Pre Colonoscopy in Subjects From a Guideline-Eligible Screening Population
Status: Enrolling
Updated: 8/3/2015
Mid Hudson Medical Research
mi
from
New Windsor, NY
Click here to add this to my saved trials
Head to Head Study Epi proColon and FIT
Comparison of the Performance of the Epi proColon and Fecal ImmunochemicalTest Post Colonoscopy in Subjects With Colorectal Cancer and Pre Colonoscopy in Subjects From a Guideline-Eligible Screening Population
Status: Enrolling
Updated:  8/3/2015
New York Gastroenterology Associates, LLP
mi
from
New York, NY
Head to Head Study Epi proColon and FIT
Comparison of the Performance of the Epi proColon and Fecal ImmunochemicalTest Post Colonoscopy in Subjects With Colorectal Cancer and Pre Colonoscopy in Subjects From a Guideline-Eligible Screening Population
Status: Enrolling
Updated: 8/3/2015
New York Gastroenterology Associates, LLP
mi
from
New York, NY
Click here to add this to my saved trials
Head to Head Study Epi proColon and FIT
Comparison of the Performance of the Epi proColon and Fecal ImmunochemicalTest Post Colonoscopy in Subjects With Colorectal Cancer and Pre Colonoscopy in Subjects From a Guideline-Eligible Screening Population
Status: Enrolling
Updated:  8/3/2015
Montefiore - Einstein Cancer Care Center
mi
from
New York, NY
Head to Head Study Epi proColon and FIT
Comparison of the Performance of the Epi proColon and Fecal ImmunochemicalTest Post Colonoscopy in Subjects With Colorectal Cancer and Pre Colonoscopy in Subjects From a Guideline-Eligible Screening Population
Status: Enrolling
Updated: 8/3/2015
Montefiore - Einstein Cancer Care Center
mi
from
New York, NY
Click here to add this to my saved trials
Head to Head Study Epi proColon and FIT
Comparison of the Performance of the Epi proColon and Fecal ImmunochemicalTest Post Colonoscopy in Subjects With Colorectal Cancer and Pre Colonoscopy in Subjects From a Guideline-Eligible Screening Population
Status: Enrolling
Updated:  8/3/2015
Asheville Gastroenterology Associates, P.A.
mi
from
Asheville, NC
Head to Head Study Epi proColon and FIT
Comparison of the Performance of the Epi proColon and Fecal ImmunochemicalTest Post Colonoscopy in Subjects With Colorectal Cancer and Pre Colonoscopy in Subjects From a Guideline-Eligible Screening Population
Status: Enrolling
Updated: 8/3/2015
Asheville Gastroenterology Associates, P.A.
mi
from
Asheville, NC
Click here to add this to my saved trials
Head to Head Study Epi proColon and FIT
Comparison of the Performance of the Epi proColon and Fecal ImmunochemicalTest Post Colonoscopy in Subjects With Colorectal Cancer and Pre Colonoscopy in Subjects From a Guideline-Eligible Screening Population
Status: Enrolling
Updated:  8/3/2015
Piedmont Medical Research Associates
mi
from
Winston-Salem, NC
Head to Head Study Epi proColon and FIT
Comparison of the Performance of the Epi proColon and Fecal ImmunochemicalTest Post Colonoscopy in Subjects With Colorectal Cancer and Pre Colonoscopy in Subjects From a Guideline-Eligible Screening Population
Status: Enrolling
Updated: 8/3/2015
Piedmont Medical Research Associates
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Head to Head Study Epi proColon and FIT
Comparison of the Performance of the Epi proColon and Fecal ImmunochemicalTest Post Colonoscopy in Subjects With Colorectal Cancer and Pre Colonoscopy in Subjects From a Guideline-Eligible Screening Population
Status: Enrolling
Updated:  8/3/2015
Lillestol Research LLC
mi
from
Fargo, ND
Head to Head Study Epi proColon and FIT
Comparison of the Performance of the Epi proColon and Fecal ImmunochemicalTest Post Colonoscopy in Subjects With Colorectal Cancer and Pre Colonoscopy in Subjects From a Guideline-Eligible Screening Population
Status: Enrolling
Updated: 8/3/2015
Lillestol Research LLC
mi
from
Fargo, ND
Click here to add this to my saved trials
Head to Head Study Epi proColon and FIT
Comparison of the Performance of the Epi proColon and Fecal ImmunochemicalTest Post Colonoscopy in Subjects With Colorectal Cancer and Pre Colonoscopy in Subjects From a Guideline-Eligible Screening Population
Status: Enrolling
Updated:  8/3/2015
Gastroenterology Research Consultants of Greater Cincinnati
mi
from
Cincinnati, OH
Head to Head Study Epi proColon and FIT
Comparison of the Performance of the Epi proColon and Fecal ImmunochemicalTest Post Colonoscopy in Subjects With Colorectal Cancer and Pre Colonoscopy in Subjects From a Guideline-Eligible Screening Population
Status: Enrolling
Updated: 8/3/2015
Gastroenterology Research Consultants of Greater Cincinnati
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Head to Head Study Epi proColon and FIT
Comparison of the Performance of the Epi proColon and Fecal ImmunochemicalTest Post Colonoscopy in Subjects With Colorectal Cancer and Pre Colonoscopy in Subjects From a Guideline-Eligible Screening Population
Status: Enrolling
Updated:  8/3/2015
Bend Memorial Clinic
mi
from
Bend, OR
Head to Head Study Epi proColon and FIT
Comparison of the Performance of the Epi proColon and Fecal ImmunochemicalTest Post Colonoscopy in Subjects With Colorectal Cancer and Pre Colonoscopy in Subjects From a Guideline-Eligible Screening Population
Status: Enrolling
Updated: 8/3/2015
Bend Memorial Clinic
mi
from
Bend, OR
Click here to add this to my saved trials
Head to Head Study Epi proColon and FIT
Comparison of the Performance of the Epi proColon and Fecal ImmunochemicalTest Post Colonoscopy in Subjects With Colorectal Cancer and Pre Colonoscopy in Subjects From a Guideline-Eligible Screening Population
Status: Enrolling
Updated:  8/3/2015
Independent Clinical Research, LLC
mi
from
Carrolton, TX
Head to Head Study Epi proColon and FIT
Comparison of the Performance of the Epi proColon and Fecal ImmunochemicalTest Post Colonoscopy in Subjects With Colorectal Cancer and Pre Colonoscopy in Subjects From a Guideline-Eligible Screening Population
Status: Enrolling
Updated: 8/3/2015
Independent Clinical Research, LLC
mi
from
Carrolton, TX
Click here to add this to my saved trials
Head to Head Study Epi proColon and FIT
Comparison of the Performance of the Epi proColon and Fecal ImmunochemicalTest Post Colonoscopy in Subjects With Colorectal Cancer and Pre Colonoscopy in Subjects From a Guideline-Eligible Screening Population
Status: Enrolling
Updated:  8/3/2015
Salt Lake Research, PLLC
mi
from
Salt Lake City, UT
Head to Head Study Epi proColon and FIT
Comparison of the Performance of the Epi proColon and Fecal ImmunochemicalTest Post Colonoscopy in Subjects With Colorectal Cancer and Pre Colonoscopy in Subjects From a Guideline-Eligible Screening Population
Status: Enrolling
Updated: 8/3/2015
Salt Lake Research, PLLC
mi
from
Salt Lake City, UT
Click here to add this to my saved trials